Representatives from Holmusk recently shared results from the largest analysis to date evaluating treatment of ADHD for children younger than 6.

The research team presented a poster at The American Professional Society of ADHD and Related Disorders 2022, providing new insight into the role of the two primary classes of medications used to manage cases: stimulants and non-stimulants.

The study, which analyzed data from a group of 3,769 children, was enabled by NeuroBlu, Holmusk’s large and rapidly growing database that contains real-world data for behavioral health. The large dataset derived from NeuroBlu enabled evaluation of not only the differences between the two broad classes of medications, but also the differences among specific types of medication.  

“This study adds valuable information to initial findings around treating young children with ADHD,” said Scott Kollins, PhD, Holmusk’s chief medical officer, who presented the poster. “Most interestingly, our large dataset derived from our NeuroBlu database enabled us to learn more about specific types of treatment and showed us the benefit of drilling down beyond medication class, underscoring the importance of leveraging real-world evidence to improve care. While guidelines still recommend behavioral therapies be used first to manage ADHD in patients so young, it is necessary to understand which medications are most effective and tolerable when caring for patients who can benefit from pharmacological treatments.”

In addition to Kollins, Holmusk's Mina Boazak, MD, MMCi, also contributed to the study.